Northland Capital Markets Starts Sensus Healthcare (SRTS) at Outperform (Earlier)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Northland Capital Markets initiates coverage on Sensus Healthcare (NASDAQ: SRTS) with a Outperform rating and a price target of $8.00.
Analyst Suraj Kalia commented, "We are initiating coverage of Sensus Healthcare with an Outperform rating / $8 PT, which represents 6x forward P/S. Sensus superficial x-ray therapy (SRT) presents a unique tool in the armamentarium of treating non-melanoma skin cancer, keloids, psoriasis and intra-operative radiation. Our constructive stance is a reflection of SRT's ability to improve ROI for clinicians while providing similar / better clinical outcomes for patients, without the side effects associated with traditional therapy."
Shares of Sensus Healthcare closed at $6.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Securities Downgrades Community Health (CYH) to Underperform
- Jefferies Raises Price Target on Coca Cola (KO) to $46 Following 3Q; Reaffirmed Guidance
- Edwards Lifesciences (EW) PT Lowered to $114 at Stifel, 'Buy' Kept
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!